Bimekizumab Lowers Uveitis Rates in Axial Spondyloarthritis

In patients with axial spondyloarthritis, bimekizumab — a dual interleukin-17A/F inhibitor — showed a lower incidence rate of uveitis, suggesting protective effects against acute anterior uveitis.
Medscape Medical News